Immunofusion
ActiveSummary
The computed 12-month bankruptcy probability of Immunofusion is 3.5% (moderate). The 2025 annual accounts show negative equity (-€126,049) and a net result of -€42,606. Equity is shrinking by about 69% per year across the filed financial years. Its solvency ranks better than 5% of 271 sector peers (NACE 72, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Immunofusion was incorporated on 4 August 2023 as a private limited company by IMUNOVAKCINA LTD, with a starting capital of €3,000.12 The registered office was moved to Gosselies in 2025.3 Since 2026, Anzhelika YURIEVA has served as director of the company.4 Total assets rose from €2,262 in 2023 to €32,131 in 2025.5
Acts, filings and financial milestones
29-09
Gazette deed
Resignation: Aleksandra BOBKOVA-ROGATNIKOVA (director)Director discharge · Power of attorney5 facts ▸
- General meeting, 20-07-2026
- Director resignation, Aleksandra BOBKOVA-ROGATNIKOVA (director)
- Director discharge, Aleksandra BOBKOVA-ROGATNIKOVA
- Board composition, Anzhelika YURIEVA (director)
- Power of attorney, RSM InterFiduciaire BV
16-07
Gazette deed
Appointment: Anzhelika YURIEVA (director)4 facts ▸
- General meeting, 21-04-2026
- Director appointment, Anzhelika YURIEVA (director)
- Board composition, Aleksandra BOBKOVA-ROGATNIKOVA (director)
- Board composition, Anzhelika YURIEVA (director)
28-03
Gazette deed
Registered office · MiscellaneousRegistered-office move · Amendment of the articles2 facts ▸
- Registered-office move, 6041 Gosselies, Rue Clément Ader, 10, (South Charleroi BioPark Dev)
- Amendment of the articles
28-03
Gazette deed
Registered office · Amendment of the articlesRegistered-office move3 facts ▸
- General meeting, “adoptée, unanimité des voix” (deed in Dutch)
- General meeting, “transfert du siège en Région wallonne, arrêter les statuts en langue française” (deed in Dutch)
- Registered-office move, 6041 Gosselies,Rue Clément Ader,10,(South Charleroi BioPark Dev)
08-08
Gazette deed
IncorporationAppointment: BOBKOVA-ROGATNIKOVA Aleksandra (director) · Founder · Founding capital15 facts ▸
- Founder, IMUNOVAKCINA LTD
- Other provision, “bijlage 1, vertegenwoordiging bij oprichtingsakte” (deed in Dutch)
- Incorporation, “Immunofusion” (deed in Dutch)
- Founding capital, €3,000
- Other provision, “kosten-oprichting, vennootschap” (deed in Dutch)
- Other provision, “financieel-plan, voorlegging aan notaris” (deed in Dutch)
- Other provision, “aansprakelijkheid-oprichters, faillissement binnen drie jaar na oprichting” (deed in Dutch)
- Other provision, “naleving-voorwaarden-oprichting, vaststelling door notaris dat akte voldoet” (deed in Dutch)
- Other provision, “vaststelling-statuten-overgangsbepalingen, bepaling statuten en overgangsbepalingen” (deed in Dutch)
- Director appointment, BOBKOVA-ROGATNIKOVA Aleksandra (director)
- Pre-incorporation commitments, “takeover, alle gestelde verbintenissen genomen door de oprichter in haar naam binnen de door het Wetboek voorziene termijnen” (deed in Dutch)
- Other provision, “Uitvoering van het voorwerp-voorafgaande toelatingen of vergunningen, vennootschap kan verplicht zijn nodige voorafgaande toelatingen of vergunningen te bekomen…” (deed in Dutch)
- +3 further facts in this act